- Home
- DSY vs BYSI Comparison
DSY vs BYSI Comparison
Compare DSY & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSY
- BYSI
- Stock Information
- Founded
- DSY 2020
- BYSI 2010
- Country
- DSY China
- BYSI United States
- Employees
- DSY N/A
- BYSI N/A
- Industry
- DSY
- BYSI Biotechnology: Pharmaceutical Preparations
- Sector
- DSY
- BYSI Health Care
- Exchange
- DSY Nasdaq
- BYSI Nasdaq
- Market Cap
- DSY 58.8M
- BYSI 67.3M
- IPO Year
- DSY N/A
- BYSI 2017
- Fundamental
- Price
- DSY $1.25
- BYSI $1.75
- Analyst Decision
- DSY
- BYSI
- Analyst Count
- DSY 0
- BYSI 0
- Target Price
- DSY N/A
- BYSI N/A
- AVG Volume (30 Days)
- DSY 45.4K
- BYSI 20.0K
- Earning Date
- DSY 02-10-2025
- BYSI 05-12-2025
- Dividend Yield
- DSY N/A
- BYSI N/A
- EPS Growth
- DSY 120.37
- BYSI N/A
- EPS
- DSY 0.01
- BYSI N/A
- Revenue
- DSY $7,323,356.00
- BYSI N/A
- Revenue This Year
- DSY N/A
- BYSI N/A
- Revenue Next Year
- DSY N/A
- BYSI N/A
- P/E Ratio
- DSY $101.45
- BYSI N/A
- Revenue Growth
- DSY 16.37
- BYSI N/A
- 52 Week Low
- DSY $0.75
- BYSI $0.98
- 52 Week High
- DSY $6.98
- BYSI $2.97
- Technical
- Relative Strength Index (RSI)
- DSY 38.53
- BYSI 54.76
- Support Level
- DSY $1.21
- BYSI $1.62
- Resistance Level
- DSY $1.51
- BYSI $1.77
- Average True Range (ATR)
- DSY 0.09
- BYSI 0.09
- MACD
- DSY -0.03
- BYSI -0.01
- Stochastic Oscillator
- DSY 0.02
- BYSI 73.53
About DSY Big Tree Cloud Holdings Limited Ordinary Shares
Big Tree Cloud Holdings Ltd is a consumer-oriented, mission-driven, and technology-empowered company engaged in the development, production, and sales of personal care products and other consumer goods. In particular, it is focused on the development and production of feminine pads and other feminine hygiene products. Through its platform, the company focuses on high-quality product development, deep customer engagement, and efficient sales and marketing.
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment.